KALA BIO, Inc. develops a dual strategy that combines a clinical-stage biologics pipeline for rare and severe eye diseases with an on-premises artificial intelligence infrastructure platform for biotechnology and pharmaceutical clients. Company updates cover the MSC-S platform, the KPI-012 clinical program, Researgency.ai, and the Bionic Intelligence Research Agent for secure research, clinical, regulatory, and data-workflow applications.
News also addresses capital-structure actions and corporate-status developments, including registered equity offerings, debt settlement, Nasdaq listing matters, governance changes, and the completed 1-for-50 reverse stock split of KALA common stock.
Kala Pharmaceuticals (NASDAQ: KALA) announced FDA approval for EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, marking it as the first prescription therapy for short-term treatment of dry eye disease. This innovative therapy utilizes Kala's AMPPLIFY Drug Delivery Technology to enhance the drug's effectiveness. EYSUVIS is set to launch in the U.S. by year-end, aiming to address the significant unmet needs of approximately 80% of patients experiencing episodic dry eye flares. The FDA's approval is based on substantial clinical trial results demonstrating rapid relief from symptoms.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced the grant of non-statutory stock options to four new employees, totaling 42,000 shares. These options, with an exercise price of $8.01 per share, were provided as inducement awards outside the 2017 Equity Incentive Plan, in line with NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, the options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. Kala focuses on innovative therapies for eye diseases, including its product INVELTYS and the investigational EYSUVIS, for which a New Drug Application is under FDA review with a target action date of October 30, 2020.